RADIANCE-HTN SOLO试验:超声肾去神经术后6个月药物滴定结果
RADIANCE-HTN SOLO随机假手术对照试验显示,未用降压药的高血压患者接受超声肾去神经术(RDN)后2个月动态收缩压较假手术组多降6.3 mm Hg;6个月时按标准阶梯治疗滴定,RDN组用药更少但日间动态收缩压仍多降4.3 mm Hg(95%CI -7.9至-0.6,P=0.024),两组无重大不良事件。
要点
- RDN组6个月时65.2%接受标准阶梯治疗,低于假手术组的84.5%(P=0.008)。
- RDN组平均降压药数量0.9±0.9 vs 假手术组1.3±0.9(P=0.010)。
- 调整基线血压和用药数后,RDN组日间动态收缩压多降4.3 mm Hg(95%CI -7.9至-0.6,P=0.024)。
核心结论
- 超声RDN的降压效应在6个月时仍维持,且所需降压药物少于假手术对照组。
研究设计与样本
- 多中心、国际、随机、盲法、假手术对照试验,纳入未用降压药的高血压患者,随机分为RDN组(n=74)和假手术组(n=72)。
主要发现
- 6个月时RDN组69/74例、假手术组71/72例完成动态血压测量。
- RDN组65.2%接受标准阶梯治疗,假手术组84.5%(P=0.008)。
- RDN组平均降压药数量0.9±0.9 vs 假手术组1.3±0.9(P=0.010),定义日剂量1.4±1.5 vs 2.0±1.8(P=0.018)。
- RDN组日间动态收缩压降低-18.1±12.2 mm Hg,假手术组-15.6±13.2 mm Hg;调整基线血压和用药数后差异为-4.3 mm Hg(95%CI -7.9至-0.6,P=0.024)。
- 两组至6个月均无重大不良事件。
关键数值与推荐
- 入组条件:停用最多2种降压药4周后,日间动态血压≥135/85 mm Hg且<170/105 mm Hg,肾动脉解剖适合。
- 阶梯治疗:2-5个月期间若家庭血压≥135/85 mm Hg,依次加用氨氯地平5 mg/d、标准剂量ACEI/ARB、氢氯噻嗪12.5 mg/d,之后依次上调氢氯噻嗪至25 mg/d、氨氯地平至10 mg/d。
临床怎么用
- 对于未用降压药的高血压患者,超声RDN可在减少药物负担的同时进一步降低日间动态收缩压。
- RDN术后仍需按标准阶梯方案进行血压管理,但部分患者所需药物更少。
局限性
- 6个月结果,长期疗效和安全性需更长时间随访。
- 样本量较小(RDN组74例,假手术组72例),完成6个月动态血压测量者RDN组69例、假手术组71例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The multicenter, international, randomized, blinded, sham-controlled RADIANCE-HTN SOLO trial (A Study of the ReCor Medical Paradise System in Clinical Hypertension) demonstrated a 6.3 mm Hg greater reduction in daytime ambulatory systolic blood pressure (BP) at 2 months by endovascular ultrasound renal denervation (RDN) compared with a sham procedure among patients not treated with antihypertensive medications. We report 6-month results after the addition of a recommended standardized stepped-care antihypertensive treatment to the randomized endovascular procedure under continued blinding to initial treatment. METHODS: Patients with a daytime ambulatory BP ≥135/85 mm Hg and <170/105 mm Hg after a 4-week discontinuation of up to 2 antihypertensive medications, and a suitable renal artery anatomy, were randomized to RDN (n=74) or sham (n=72). Patients were to remain off antihypertensive medications throughout the first 2 months of follow-up unless safety BP criteria were exceeded. Between 2 and 5 months, if monthly measured home BP was ≥135/85 mm Hg, a standardized stepped-care antihypertensive treatment was recommended consisting of the sequential addition of amlodipine (5 mg/d), a standard dose of an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, and hydrochlorothiazide (12.5 mg/d), followed by the sequential uptitration of hydrochlorothiazide (25 mg/d) and amlodipine (10 mg/d). Outcomes included the 6-month (1) change in daytime ambulatory systolic BP adjusted for medications and baseline systolic BP, (2) medication burden, and (3) safety. RESULTS: A total of 69/74 RDN patients and 71/72 sham patients completed the 6-month ambulatory BP measurement. At 6 months, 65.2% of patients in the RDN group were treated with the standardized stepped-care antihypertensive treatment versus 84.5% in the sham group (P=0.008), and the average number of antihypertensive medications and defined daily dose were less in the RDN group than in the sham group (0.9±0.9 versus 1.3±0.9, P=0.010 and 1.4±1.5 versus 2.0±1.8, P=0.018; respectively). Despite less intensive standardized stepped-care antihypertensive treatment, RDN reduced daytime ambulatory systolic BP to a greater extent than sham (-18.1±12.2 versus -15.6±13.2 mm Hg, respectively; difference adjusted for baseline BP and number of medications: -4.3 mm Hg, 95% confidence interval, -7.9 to -0.6, P=0.024). There were no major adverse events in either group through 6 months. CONCLUSIONS: The BP-lowering effect of endovascular ultrasound RDN was maintained at 6 months with less prescribed antihypertensive medications compared with a sham control. CLINICAL TRIAL REGISTRATION: URL: https://www. CLINICALTRIALS: gov. Unique identifier: NCT02649426.
引用
- Azizi M, Schmieder RE, Mahfoud F, et al. Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control After Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial. Circulation. 2019. PMID: 30880441. doi:10.1161/CIRCULATIONAHA.119.040451
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。